ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.
Based on research in post-surgery patients, the FDA approved suzetrigine, a non-opioid analgesic, for the treatment moderate to severe, acute pain in adults.
The FDA accepted a new drug application for suzetrigine, a non-opioid analgesic, based on the results from clinical trials in patients with neuropathy and those post-surgery.